A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

  • STATUS
    Recruiting
  • End date
    Jul 25, 2024
  • participants needed
    706
  • sponsor
    Sun Yat-sen University
Updated on 24 January 2021

Summary

This study evaluates the addition of Tenofovir and Entecavir in the treatment of Hepatitis B-related hepatocellular carcinoma after curative resection in adults. Half of participants will receive Tenofovir disoproxil fumarate, while the other half will receive Entecavir.

Description

Antiviral potency significantly differs among various antiviral agentsEntecavir and tenofovir disoproxil fumarate are equally recommendedas first-line treatments for patients with chronic hepatitis B (CHB). However, it is unclear whether treatment with these drugs is associated with equivalent clinical outcomes,especially impacts the risk of HCC recurrence. Entecavir and tenofovir disoproxil fumarate have comparable efficacy in achieving surrogate end points, including virologic response,but they do by different mechanisms .

Entecavir, a guanosine nucleoside analogue with activity against HBV reverse transcriptase (rt),is efficiently phosphorylated to the active triphosphate form, which has an intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine triphosphate, entecavir triphosphate functionally inhibits all three activities of the HBV reverse transcriptase: (1) basepriming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA,and (3) synthesis of the positive strand of HBV DNA.

Tenofovir fumarate is a cyclic nucleoside phosphine diester structural analog of adenosine monophosphate. Tenofovir disoproxil fumarate first needs to be converted to tenofovir by hydrolysis of the diester, followed by phosphorylation of cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate competes with the natural substrate 5'-deoxyadenosine triphosphate for its involvement in the synthesis of viral DNA, which, after entering the viral DNA strand, can cause DNA elongation to be blocked due to its lack of 3'-OH groups,thereby blocking the replication of the virus. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerase alpha, beta and mitochondrial DNA polymerase gamma.

Details
Condition Hepatocellular Carcinoma Recurrent, Recurrent Hepatocellular Carcinoma
Treatment Entecavir 0.5 mg, Tenofovir disoproxil fumarate 300mg
Clinical Study IdentifierNCT04392700
SponsorSun Yat-sen University
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 80 yrs?
Gender: Male or Female
Do you have Hepatocellular Carcinoma Recurrent?
Do you have any of these conditions: Hepatocellular Carcinoma Recurrent or Recurrent Hepatocellular Carcinoma?
age 18 to 70 years
Positive test for hepatitis B surface antigen (HBsAg) and negative tests for antibodies to hepatitis C virus (HCV-Ab) or to human immunodeficiency virus
Clinical diagnosis is consistent with HCC and histopathological result of the resected specimens being HCC
No previous treatment of HCC and no previous treatment of hepatitis B with nucleoside or nucleotide analogues or both; no previous treatment with interferon or other immunomodulators
BCLC stage 0, A or a solitary tumor with a diameter >5cm
No extrahepatic metastasisc
No radiologic evidence of invasion into major portal/hepatic venous branches
Good liver function with Child-Pugh Class A or Child - Pugh Class B (If B Child - Pugh score 7 ) and baseline serum alanine aminotransferase (ALT) level less than 3 times the upper limit of normal (reference range <40IU/L), with no history of encephalopathy, ascites refractory to diuretics, esophagogastric variceal bleeding
Good renal function (a serum creatinine level<133mmol/L)
Negative resection margin (R0 resection)
Laboratory blood tests : WBC3.010^9/L ; PLT7510^9/L ; Hb100g/L Cr<133mmol/L ; ALT 150U/L ; AST 120U/L ; ALB30g/L ; TBIL34mmol/L INR < 1.5 ; APTT < 18 S

Exclusion Criteria

Eligible patients were excluded if they refused to participate
Histopathological result of the resected specimens being not HCC
History of antiviral therapy
History of receive treatment of HCC include drugs radiofrequency ablation transcatheter arterial chemoembolization or resection
age 18 or 70 years
Pregnant or lactating women
Poor liver function and poor renal function
Suffering from other serious acute or chronic physical or mental illness
The following occurred before the study beganMyocardial infarction Unstable anginaCoronary artery bypass surgeryCerebrovascular Pulmonary embolism
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note